Candriam S.C.A. Buys 3,517 Shares of Revvity, Inc. (NYSE:RVTY)

Candriam S.C.A. increased its position in shares of Revvity, Inc. (NYSE:RVTY - Free Report) by 39.2% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 12,478 shares of the company's stock after purchasing an additional 3,517 shares during the period. Candriam S.C.A.'s holdings in Revvity were worth $1,393,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Gladius Capital Management LP purchased a new position in Revvity during the third quarter worth about $32,000. Assetmark Inc. increased its holdings in Revvity by 3,700.0% in the fourth quarter. Assetmark Inc. now owns 266 shares of the company's stock valued at $30,000 after buying an additional 259 shares in the last quarter. Continuum Advisory LLC increased its holdings in Revvity by 2,972.7% in the third quarter. Continuum Advisory LLC now owns 338 shares of the company's stock valued at $43,000 after buying an additional 327 shares in the last quarter. MassMutual Private Wealth & Trust FSB increased its holdings in Revvity by 55.9% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 385 shares of the company's stock valued at $43,000 after buying an additional 138 shares in the last quarter. Finally, Avior Wealth Management LLC increased its holdings in Revvity by 7,980.0% in the third quarter. Avior Wealth Management LLC now owns 404 shares of the company's stock valued at $52,000 after buying an additional 399 shares in the last quarter. 86.65% of the stock is owned by hedge funds and other institutional investors.

Revvity Stock Down 1.1 %

RVTY traded down $1.23 on Thursday, reaching $110.29. 1,479,916 shares of the company traded hands, compared to its average volume of 967,167. The company has a debt-to-equity ratio of 0.41, a current ratio of 3.60 and a quick ratio of 3.03. The company has a market cap of $13.25 billion, a price-to-earnings ratio of 49.91, a PEG ratio of 3.82 and a beta of 1.06. Revvity, Inc. has a 52-week low of $97.32 and a 52-week high of $129.50. The stock's 50 day moving average price is $117.08 and its 200-day moving average price is $118.10.

Remove Ads

Revvity (NYSE:RVTY - Get Free Report) last posted its earnings results on Friday, January 31st. The company reported $1.42 EPS for the quarter, topping the consensus estimate of $1.37 by $0.05. Revvity had a net margin of 9.81% and a return on equity of 7.68%. During the same period in the prior year, the business earned $1.25 earnings per share. On average, sell-side analysts expect that Revvity, Inc. will post 4.94 EPS for the current fiscal year.

Revvity Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, May 9th. Investors of record on Friday, April 18th will be paid a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a yield of 0.25%. The ex-dividend date of this dividend is Thursday, April 17th. Revvity's payout ratio is currently 12.67%.

Insider Activity at Revvity

In other news, insider Tajinder S. Vohra sold 5,492 shares of the stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $116.81, for a total value of $641,520.52. Following the completion of the transaction, the insider now owns 19,652 shares in the company, valued at approximately $2,295,550.12. This represents a 21.84 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Joel S. Goldberg sold 15,170 shares of the stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $126.73, for a total transaction of $1,922,494.10. Following the completion of the transaction, the insider now owns 33,400 shares of the company's stock, valued at approximately $4,232,782. This represents a 31.23 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.60% of the company's stock.

Analyst Ratings Changes

A number of brokerages have issued reports on RVTY. Bank of America raised shares of Revvity from a "neutral" rating to a "buy" rating and set a $138.00 target price for the company in a report on Friday, December 13th. KeyCorp raised their target price on shares of Revvity from $132.00 to $145.00 and gave the company an "overweight" rating in a research note on Monday, February 3rd. Barclays lifted their price target on shares of Revvity from $135.00 to $140.00 and gave the stock an "overweight" rating in a research note on Monday, February 3rd. Raymond James reaffirmed an "outperform" rating and issued a $145.00 price target (up from $140.00) on shares of Revvity in a report on Monday, February 3rd. Finally, Sanford C. Bernstein lowered shares of Revvity from an "outperform" rating to a "market perform" rating and set a $130.00 price target for the company. in a report on Friday, January 10th. Four equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Revvity presently has a consensus rating of "Moderate Buy" and an average target price of $136.25.

Revvity Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.